We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Clinical Updates

Minimal Equipment Pulmonary Rehabilitation Matches Specialized Gym-Based Programs: New RCT Evidence

MedXY Editorial Team•Oct 4, 2025•Clinical Updates
chronic respiratory diseaseclinical trialexercise capacitypulmonary rehabilitation

Highlight

This randomized clinical trial compared traditional gym-equipment pulmonary rehabilitation (PR-gym) versus a minimal equipment model (PR-min) in patients with chronic respiratory disease. PR-min was found to be noninferior in improving exercise capacity, dyspnea, and health-related quality of life, with no increase in adverse events or costs. This supports broader accessibility to PR using minimal, easily available equipment.

Study Background and Disease Burden

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Evaluating Cusatuzumab Combined with Venetoclax ± Azacitidine in Unfit Newly Diagnosed AML: Insights from the Phase Ib ELEVATE TrialThe phase Ib ELEVATE study demonstrates that cusatuzumab combined with venetoclax and azacitidine offers a promising tolerable and effective frontline therapy for patients with newly diagnosed acute myeloid leukemia ineligible for intensiveSep 9, 2026Therapeutic Hypothermia at 35°C vs. Controlled Normothermia in ICU Heatstroke: Insights from a Pilot RCTA pilot randomized trial comparing targeted temperature management at 35°C versus normothermia in intubated heatstroke patients showed no survival or neurological benefit from hypothermia but increased gastrointestinal injury and arrhythmiaSep 3, 2026Gabapentin for Cough in Idiopathic Pulmonary Fibrosis: Efficacy and Safety Insights from a Randomized Controlled TrialA randomized, double-blind, placebo-controlled trial demonstrates gabapentin’s significant efficacy and acceptable safety for treating cough in IPF, supporting its clinical use amid limited alternatives.Sep 1, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Individualized vs Standard Blood Pressure Control During Mechanical Thrombectomy for Acute Ischemic Stroke: Insights from the DETERMINE Randomized Clinical Trial
A randomized clinical trial comparing individualized versus standard blood pressure control during mechanical thrombectomy for ischemic stroke showed no significant difference in 90-day functional outcomes or safety.
Aug 24, 2026
Deupirfenidone: A New Horizon in Slowing Idiopathic Pulmonary Fibrosis ProgressionDeupirfenidone, a deuterated form of pirfenidone, demonstrated efficacy in slowing lung function decline in IPF patients, with a favorable safety profile in a phase 2b trial, offering promise for improved treatment outcomes.Aug 17, 2026
Balancing Risks: Antiplatelet Therapy After Intracerebral Haemorrhage in the STATICH TrialThe STATICH trial assessed safety and efficacy of antiplatelet therapy after intracerebral hemorrhage, revealing increased hemorrhagic risk but fewer ischemic events among treated patients, highlighting ongoing clinical dilemmas.Aug 18, 2026